In early September, a closely watched Phase 3 trial revealed that pelacarsen — a drug developed by Novartis and Ionis to target lipoprotein(a), a cholesterol particle long linked to heart disease — failed to deliver the cardiovascular risk reduction researchers had hoped for. The result is a reminder that the distance between biological promise and clinical proof is rarely as short as ambition suggests. For millions of patients carrying elevated Lp(a) levels without adequate treatment options, the wait for a meaningful answer grows longer, even as the scientific community is left to reckon wit
Novartis Lp(a) drug pelacarsen fails to reduce cardiovascular risk in Phase 3 trial
The gap between lowering a biomarker and saving lives
Mark
So pelacarsen was supposed to lower Lp(a) and reduce heart attacks. It lowered Lp(a) but didn't reduce heart attacks. Is that what happened?
Mimi
That's the core of it, yes. The drug did what it was designed to do at the molecular level—it reduced Lp(a) in the blood. But when they looked at whether patients actually had fewer cardiovascular events, the answer was no. That's the primary endpoint they missed.
Luke
Wait—do we know for certain that Lp(a) levels actually dropped? Or are we taking that as assumed because the mechanism should work?
Mimi
The reporting focuses on the primary endpoint failure. I'd say the Lp(a) reduction is implied by the mechanism, but you're right to push back. The headlines don't explicitly state the biomarker results.
Mark
Why would lowering a risk factor not reduce the risk? That seems backwards.
Mimi
It happens more often than people realize. A biomarker can move in the right direction without translating to clinical benefit. It could mean Lp(a) isn't as causal as we thought, or that the dose wasn't high enough, or that other factors matter more than we expected.
Luke
Or it could mean the trial wasn't powered correctly, or the patient population wasn't right. We don't have those details from the reporting.
Mark
What does this mean for other Lp(a) drugs in development?
Mimi
It casts doubt on the whole category. If pelacarsen—which had solid early data and backing from two major companies—can't show benefit, investors and regulators will be more cautious about approving similar drugs.
Luke
Though it's worth noting: one failed trial doesn't prove the Lp(a) hypothesis is wrong. It proves this particular drug, in this particular trial, didn't work. That's different.
Mark
Fair. So what's the next move for Novartis and Ionis?
Mimi
They could dig deeper into the data, try the drug in a different patient group, or walk away. The stock market's reaction suggests investors think the latter is most likely.
El Pulso
- A drug that had generated genuine excitement among cardiologists and investors alike collapsed at the final hurdle, failing to reduce major cardiovascular events in the patients it was designed to protect.
- The announcement triggered immediate after-hours selloffs across Novartis, Ionis, and Amgen, signaling that markets read the failure not as a single setback but as a shadow cast over the entire Lp(a) therapeutic space.
- The result exposed a troubling gap: lowering Lp(a) levels in the blood did not appear to translate into the real-world clinical benefit the biological rationale had promised, forcing a fundamental rethink of how the target should be approached.
- Competing companies pursuing alternative Lp(a)-lowering strategies now face a more skeptical regulatory and investment climate, with the burden of proof raised considerably higher than it was before.
- Novartis and Ionis must now decide whether to dig deeper into the trial data, test different patient populations, or redirect their resources — while patients with elevated Lp(a) and high cardiovascular risk remain without a proven therapeutic option.
In early September, a closely watched Phase 3 trial revealed that pelacarsen — a drug developed by Novartis and Ionis to target lipoprotein(a), a cholesterol particle long linked to heart disease — failed to deliver the cardiovascular risk reduction researchers had hoped for. The result is a reminder that the distance between biological promise and clinical proof is rarely as short as ambition suggests. For millions of patients carrying elevated Lp(a) levels without adequate treatment options, the wait for a meaningful answer grows longer, even as the scientific community is left to reckon with what the data is truly saying.
In early September, Novartis and Ionis disclosed that pelacarsen, their experimental drug targeting lipoprotein(a), had failed its Phase 3 clinical trial. The drug did not produce a meaningful reduction in cardiovascular events among patients with elevated Lp(a) — a result that stunned both the cardiology community and financial markets.
Lp(a) has grown in prominence over the past decade as a significant and poorly addressed risk factor for heart attack and stroke. Statins, the standard cholesterol treatment, do little to affect it. Pelacarsen used antisense oligonucleotide therapy to reduce the body's production of the protein itself, and its scientific rationale had drawn serious attention. Earlier-stage trials had shown promise, and the medical need was undeniable.
The Phase 3 failure cut deeper than disappointment in a single drug. It raised a harder question: whether lowering Lp(a) levels in the blood actually translates into better outcomes for patients. The gap between biomarker improvement and clinical benefit is a familiar problem in medicine, but its appearance here shook confidence in the entire field.
Markets responded sharply, with after-hours declines for Novartis, Ionis, and Amgen — a signal that investors saw the result as a broader indictment of the Lp(a) space, not just one compound. Other companies working on similar strategies now face a more demanding environment for both regulatory approval and investment.
What comes next is uncertain. Novartis and Ionis may pursue further analysis or explore different patient populations. The cardiology field will need to reassess which approaches to Lp(a) still merit pursuit. For patients, the setback means the search for a proven treatment continues.
Novartis and Ionis announced in early September that pelacarsen, their experimental drug designed to lower lipoprotein(a)—a cholesterol particle linked to heart disease—failed to achieve its primary goal in a Phase 3 clinical trial. The drug did not demonstrate a meaningful reduction in cardiovascular risk among patients with elevated Lp(a) levels, a result that upended expectations across the cardiology and investment communities.
Lp(a) has emerged over the past decade as a significant risk factor for heart attack and stroke, one that existing cholesterol medications like statins do not adequately address. Pelacarsen represented a direct attempt to lower Lp(a) through a mechanism called antisense oligonucleotide therapy—essentially a molecular tool designed to reduce production of the protein itself. The drug had drawn considerable attention from cardiologists and pharmaceutical investors precisely because the medical need was clear and the mechanism seemed promising. Novartis and Ionis had positioned it as a potential breakthrough for millions of patients at elevated cardiovascular risk.
The trial's failure to meet its primary endpoint—the reduction in major cardiovascular events—sent shockwaves through the market. After-hours trading saw sharp declines for Novartis, Ionis, and Amgen, which had partnerships or commercial interests tied to Lp(a) therapeutics. The selloff reflected not just disappointment in a single drug candidate, but broader uncertainty about whether the Lp(a) space itself would yield the transformative treatments the field had anticipated.
For cardiologists who had followed pelacarsen's development closely, the result was particularly striking. The drug had shown promise in earlier-stage trials, and the biological rationale for targeting Lp(a) remained sound. Yet the Phase 3 data suggested that simply lowering Lp(a) levels in the blood might not translate into the clinical benefit researchers had projected. This gap between biomarker improvement and actual patient outcomes raised fundamental questions about how Lp(a) should be approached therapeutically.
The failure also reshaped the competitive landscape for cardiovascular drug development. Other companies pursuing Lp(a)-lowering strategies—whether through different molecular mechanisms or alternative approaches—now faced a more skeptical regulatory and investment environment. The pelacarsen result suggested that the path to an effective Lp(a) therapy would be more complex and uncertain than the initial enthusiasm had implied.
What happens next remains unclear. Novartis and Ionis will need to determine whether to pursue additional analyses of the trial data, explore pelacarsen in different patient populations, or redirect resources elsewhere. The broader cardiology field will likely reassess which Lp(a) strategies deserve continued investment and clinical attention. For patients with elevated Lp(a) and high cardiovascular risk, the setback means the wait for a proven treatment continues.
Citas Notables
The result shocked cardiologists and investors who had expected pelacarsen to demonstrate meaningful cardiovascular benefit— Industry observers and market reaction
Quieres la nota completa?
Lee el original en Google News ↗
Health & Medicine